Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2000
Single User License Price INR 146940
Corporate User License Price USD 6000
Corporate User License Price INR 440820
Site License Price USD 4000
Site License Price INR 293880
Request a Quote

Report Title

Osteoporosis-Pipeline Review, H1 2017

Quote Request for License Type
License Type Price  
Single User License USD 2000
Site License USD 4000
Enterprise Wide License USD 6000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Osteoporosis-Pipeline Review, H1 2017


Quote Request for License Type
License Type Price  
Single User License USD 2000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Osteoporosis-Pipeline Review, H1 2017

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Osteoporosis-Pipeline Review, H1 2017



Executive Summary

Osteoporosis-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis-Pipeline Review, H1 2017, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.

Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoporosis-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 5, 5, 11, 57, 11 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 10 and 13 molecules, respectively.

Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Osteoporosis-Overview 10

Osteoporosis-Therapeutics Development 11

Pipeline Overview 11

Pipeline by Companies 12

Pipeline by Universities/Institutes 18

Products under Development by Companies 19

Products under Development by Universities/Institutes 25

Osteoporosis-Therapeutics Assessment 27

Assessment by Target 27

Assessment by Mechanism of Action 30

Assessment by Route of Administration 33

Assessment by Molecule Type 35

Osteoporosis-Companies Involved in Therapeutics Development 37

Addex Therapeutics Ltd 37

Alize Pharma SAS 37

Alvogen Korea Co Ltd 38

Amgen Inc 38

Amura Holdings Ltd 39

BiologicsMD Inc 39

Bone Biologics Corp 40

Bristol-Myers Squibb Company 40

Cellmid Ltd 41

ChoDang Pharm Co Ltd 41

Chugai Pharmaceutical Co Ltd 42

Corium International Inc 42

Critical Pharmaceuticals Ltd 43

Daiichi Sankyo Company Ltd 43

ElexoPharm GmbH 44

EndoCeutics Inc 44

Entera Bio Ltd 45

Enteris BioPharma Inc 45

Enzo Biochem Inc 46

F. Hoffmann-La Roche Ltd 46

Gador SA 47

GL Pharm Tech Corp 47

Glide Pharmaceutical Technologies Ltd 48

Hanmi Pharmaceuticals Co Ltd 48

Haoma Medica Ltd 49

Immunovo BV 49

Immunwork Inc 50

Intas Pharmaceuticals Ltd 50

Ipsen SA 51

Kaken Pharmaceutical Co Ltd 51

Lead Discovery Center GmbH 52

Ligand Pharmaceuticals Inc 52

Lotus Pharmaceutical Co Ltd 53

Lupin Ltd 53

Merck & Co Inc 54

Mereo Biopharma Group Plc 54

NIBEC 55

Omeros Corp 55

Oncobiologics Inc 56

Osteologix Holdings Plc 56

Paras Biopharmaceuticals Finland Oy 57

Pfenex Inc 57

PhytoHealth Corp 58

R Pharm 58

Ribomic Inc 59

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd 59

Shin Poong PharmCo Ltd 60

Sinil Pharmaceutical Co Ltd 60

Stelis Biopharma Pvt Ltd 61

Sumitomo Dainippon Pharma Co Ltd 61

Terpenoid Therapeutics Inc 62

TSH Biopharm Corporation Ltd 62

Uni-Bio Science Group Ltd 63

Viking Therapeutics Inc 63

Wroclawskie Centrum Badan EIT+ Sp z oo 64

Yooyoung Pharm Co Ltd 64

Zydus Cadila Healthcare Ltd 65

Osteoporosis-Drug Profiles 66

(acolbifene hydrochloride + prasterone)-Drug Profile 66

(cholecalciferol + raloxifene)-Drug Profile 67

(cholecalciferol + risedronate sodium)-Drug Profile 68

2-AMD-Drug Profile 69

3D-QM-Drug Profile 70

3D-QMS-Drug Profile 71

abaloparatide-Drug Profile 72

ADX-68693-Drug Profile 80

AKR-215-Drug Profile 81

AKR-308-Drug Profile 82

alendronate sodium-Drug Profile 83

AM-3701-Drug Profile 84

ARC-205-Drug Profile 85

BCD-700-Drug Profile 86

BMD-1111-Drug Profile 87

BMS-777607-Drug Profile 88

BPS-804-Drug Profile 90

calcitonin DR-Drug Profile 92

CD-030-Drug Profile 96

CDR-914K058-Drug Profile 97

CDRI-99/373-Drug Profile 98

CH-5036249-Drug Profile 99

denosumab-Drug Profile 100

denosumab biosimilar-Drug Profile 109

denosumab biosimilar-Drug Profile 110

denosumab biosimilar-Drug Profile 111

denosumab biosimilar-Drug Profile 112

Drugs to Chelate Iron for Bone Degeneration, Postmenopausal Osteoporosis and Thalassemia-Drug Profile 113

Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders-Drug Profile 114

DS-1501-Drug Profile 115

eldecalcitol-Drug Profile 116

Eu-232-Drug Profile 117

Ewha-18278-Drug Profile 118

genipin-Drug Profile 119

HCP-1405-Drug Profile 120

HCP-1604-Drug Profile 121

IG-8801-Drug Profile 122

IHBD-1-Drug Profile 123

IPS-02001-Drug Profile 124

KAL-671-Drug Profile 125

KKM-0805-Drug Profile 127

KKM-0902-Drug Profile 128

KN-012-Drug Profile 129

lasofoxifene tartrate-Drug Profile 130

MAb-4-Drug Profile 133

MDY-1001-Drug Profile 134

Monoclonal Antibody to Inhibit Midkine for Bone Fractures-Drug Profile 135

Monoclonal Antibody to Inhibit Sclerostin for Osteoporosis-Drug Profile 136

NBS-101-Drug Profile 137

NEP-28-Drug Profile 138

OGX-528-Drug Profile 139

OXY-133-Drug Profile 140

OXY-149-Drug Profile 141

OXY-153-Drug Profile 143

PF-708-Drug Profile 144

PHN-031-Drug Profile 145

Protein to Antagonize PPAR Gamma-2 for Rheumatoid Arthritis, Obesity and Osteoporosis-Drug Profile 146

Proteins to Inhibit RANKL for Oncology and Osteoporosis-Drug Profile 147

R-Spondin 1-Drug Profile 148

RBM-007-Drug Profile 149

Recombinant Peptide to Agonize PTH1R for Osteoporosis-Drug Profile 150

Recombinant Protein 1 for Osteoporosis and Rheumatoid Arthritis-Drug Profile 151

Recombinant Protein 2 for Osteoporosis and Rheumatoid Arthritis-Drug Profile 152

Recombinant Protein 3 for Osteoporosis and Rheumatoid Arthritis-Drug Profile 153

Recombinant Protein for Bone Disorders and Osteoporosis-Drug Profile 154

Recombinant Protein for Osteoporosis and Osteoarthritis-Drug Profile 155

Recombinant Protein for Osteoporosis and Rheumatoid Arthritis-Drug Profile 156

Recombinant Protein to Agonize PTH Receptor for Osteoporosis and Osteoarthritis-Drug Profile 157

Recombinant Protein to Inhibit Activin A for Osteoporosis and Cancer Cachexia-Drug Profile 158

romosozumab-Drug Profile 159

RPH-203-Drug Profile 165

S-0071500-Drug Profile 166

S-008399-Drug Profile 167

S-101479-Drug Profile 168

SI-000513-Drug Profile 169

Small Molecule for Oncology, Psoriasis and Osteoporosis-Drug Profile 170

Small Molecule for Osteoporosis-Drug Profile 171

Small Molecule to Activate sGC for Osteoporosis-Drug Profile 172

Small Molecule to Agonize Androgen Receptor for Osteoporosis-Drug Profile 173

Small Molecule to Agonize EP4 Receptor for Osteoporosis-Drug Profile 174

Small Molecule to Agonize LRP for Osteoporosis-Drug Profile 175

Small Molecule to Agonize PTH-1R for Osteoporosis-Drug Profile 176

Small Molecule to Antagonize OGR1 for Asthma, Bone Diseases, Oncology and Osteoporosis-Drug Profile 177

Small Molecule to Inhibit 17beta-HSD2 for Osteoporosis-Drug Profile 178

Small Molecule to Target GPR183 for Epstein-Barr Viral Infections and Osteoporosis-Drug Profile 179

Small Molecule to Target LGR4 for Oncology and Osteoporosis-Drug Profile 180

Small Molecule to Target Plexin-B1/Sema4D for Multiple Sclerosis and Osteoporosis-Drug Profile 181

Small Molecules for Metabolic and Musculoskeletal Disorders-Drug Profile 182

Small Molecules for Musculoskeletal and Metabolic Disorders-Drug Profile 183

Small Molecules for Osteopenia and Osteoporosis-Drug Profile 184

Small Molecules for Osteoporosis-Drug Profile 185

Small Molecules for Osteoporosis-Drug Profile 186

Small Molecules to Antagonize Calcium-Sensing Receptor for Osteoporosis-Drug Profile 188

Small Molecules to Inhibit 17Beta-HSD2 for Osteoporosis-Drug Profile 189

Small Molecules to Inhibit GGDPS for Bone Metastasis and Oncology-Drug Profile 190

Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology-Drug Profile 191

Small Molecules to Inhibit Sclerostin for Osteoporosis-Drug Profile 192

Small Molecules to Target Estrogen Receptor for Breast Cancer and Osteoporosis-Drug Profile 193

Sodium Quinate-Drug Profile 194

SP-35454-Drug Profile 195

SR-10171-Drug Profile 196

SR-2595-Drug Profile 197

Synthetic Peptide for Obesity and Post Menopausal Osteoporosis-Drug Profile 198

Synthetic Peptide for Osteoporosis-Drug Profile 199

Synthetic Peptide for Osteoporosis and Bone Fracture-Drug Profile 200

Synthetic Peptides for Ischemic Stroke, Osteoporosis and Sepsis-Drug Profile 201

TE-3110-Drug Profile 202

TE-3236-Drug Profile 203

teriparatide-Drug Profile 204

teriparatide-Drug Profile 205

teriparatide-Drug Profile 207

teriparatide-Drug Profile 208

teriparatide biosimilar-Drug Profile 209

teriparatide biosimilar-Drug Profile 210

teriparatide biosimilar-Drug Profile 211

teriparatide biosimilar-Drug Profile 212

UCB-1-Drug Profile 213

Vaccine to Target Sclerostin for Osteoporosis-Drug Profile 214

VK-5211-Drug Profile 215

VS-105-Drug Profile 218

Osteoporosis-Dormant Projects 219

Osteoporosis-Discontinued Products 226

Osteoporosis-Product Development Milestones 228

Featured News & Press Releases 228

Appendix 238

Methodology 238

Coverage 238

Secondary Research 238

Primary Research 238

Expert Panel Validation 238

Contact Us 238

Disclaimer 239

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Osteoporosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Top 10 Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

List of Tables

Number of Products under Development for Osteoporosis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Companies, H1 2017 (Contd..4), H1 2017

Products under Development by Companies, H1 2017 (Contd..5), H1 2017

Products under Development by Universities/Institutes, H1 2017

Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Osteoporosis-Pipeline by Addex Therapeutics Ltd, H1 2017

Osteoporosis-Pipeline by Alize Pharma SAS, H1 2017

Osteoporosis-Pipeline by Alvogen Korea Co Ltd, H1 2017

Osteoporosis-Pipeline by Amgen Inc, H1 2017

Osteoporosis-Pipeline by Amura Holdings Ltd, H1 2017

Osteoporosis-Pipeline by BiologicsMD Inc, H1 2017

Osteoporosis-Pipeline by Bone Biologics Corp, H1 2017

Osteoporosis-Pipeline by Bristol-Myers Squibb Company, H1 2017

Osteoporosis-Pipeline by Cellmid Ltd, H1 2017

Osteoporosis-Pipeline by ChoDang Pharm Co Ltd, H1 2017

Osteoporosis-Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017

Osteoporosis-Pipeline by Corium International Inc, H1 2017

Osteoporosis-Pipeline by Critical Pharmaceuticals Ltd, H1 2017

Osteoporosis-Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Osteoporosis-Pipeline by ElexoPharm GmbH, H1 2017

Osteoporosis-Pipeline by EndoCeutics Inc, H1 2017

Osteoporosis-Pipeline by Entera Bio Ltd, H1 2017

Osteoporosis-Pipeline by Enteris BioPharma Inc, H1 2017

Osteoporosis-Pipeline by Enzo Biochem Inc, H1 2017

Osteoporosis-Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Osteoporosis-Pipeline by Gador SA, H1 2017

Osteoporosis-Pipeline by GL Pharm Tech Corp, H1 2017

Osteoporosis-Pipeline by Glide Pharmaceutical Technologies Ltd, H1 2017

Osteoporosis-Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2017

Osteoporosis-Pipeline by Haoma Medica Ltd, H1 2017

Osteoporosis-Pipeline by Immunovo BV, H1 2017

Osteoporosis-Pipeline by Immunwork Inc, H1 2017

Osteoporosis-Pipeline by Intas Pharmaceuticals Ltd, H1 2017

Osteoporosis-Pipeline by Ipsen SA, H1 2017

Osteoporosis-Pipeline by Kaken Pharmaceutical Co Ltd, H1 2017

Osteoporosis-Pipeline by Lead Discovery Center GmbH, H1 2017

Osteoporosis-Pipeline by Ligand Pharmaceuticals Inc, H1 2017

Osteoporosis-Pipeline by Lotus Pharmaceutical Co Ltd, H1 2017

Osteoporosis-Pipeline by Lupin Ltd, H1 2017

Osteoporosis-Pipeline by Merck & Co Inc, H1 2017

Osteoporosis-Pipeline by Mereo Biopharma Group Plc, H1 2017

Osteoporosis-Pipeline by NIBEC, H1 2017

Osteoporosis-Pipeline by Omeros Corp, H1 2017

Osteoporosis-Pipeline by Oncobiologics Inc, H1 2017

Osteoporosis-Pipeline by Osteologix Holdings Plc, H1 2017

Osteoporosis-Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2017

Osteoporosis-Pipeline by Pfenex Inc, H1 2017

Osteoporosis-Pipeline by PhytoHealth Corp, H1 2017

Osteoporosis-Pipeline by R Pharm, H1 2017

Osteoporosis-Pipeline by Ribomic Inc, H1 2017

Osteoporosis-Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2017

Osteoporosis-Pipeline by Shin Poong PharmCo Ltd, H1 2017

Osteoporosis-Pipeline by Sinil Pharmaceutical Co Ltd, H1 2017

Osteoporosis-Pipeline by Stelis Biopharma Pvt Ltd, H1 2017

Osteoporosis-Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017

Osteoporosis-Pipeline by Terpenoid Therapeutics Inc, H1 2017

Osteoporosis-Pipeline by TSH Biopharm Corporation Ltd, H1 2017

Osteoporosis-Pipeline by Uni-Bio Science Group Ltd, H1 2017

Osteoporosis-Pipeline by Viking Therapeutics Inc, H1 2017

Osteoporosis-Pipeline by Wroclawskie Centrum Badan EIT+ Sp z oo, H1 2017

Osteoporosis-Pipeline by Yooyoung Pharm Co Ltd, H1 2017

Osteoporosis-Pipeline by Zydus Cadila Healthcare Ltd, H1 2017

Osteoporosis-Dormant Projects, H1 2017

Osteoporosis-Dormant Projects, H1 2017 (Contd..1), H1 2017

Osteoporosis-Dormant Projects, H1 2017 (Contd..2), H1 2017

Osteoporosis-Dormant Projects, H1 2017 (Contd..3), H1 2017

Osteoporosis-Dormant Projects, H1 2017 (Contd..4), H1 2017

Osteoporosis-Dormant Projects, H1 2017 (Contd..5), H1 2017

Osteoporosis-Dormant Projects, H1 2017 (Contd..6), H1 2017

Osteoporosis-Discontinued Products, H1 2017

Osteoporosis-Discontinued Products, H1 2017 (Contd..1), H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Addex Therapeutics Ltd, Alize Pharma SAS, Alvogen Korea Co Ltd, Amgen Inc, Amura Holdings Ltd, BiologicsMD Inc, Bone Biologics Corp, Bristol-Myers Squibb Company, Cellmid Ltd, ChoDang Pharm Co Ltd, Chugai Pharmaceutical Co Ltd, Corium International Inc, Critical Pharmaceuticals Ltd, Daiichi Sankyo Company Ltd, ElexoPharm GmbH, EndoCeutics Inc, Entera Bio Ltd, Enteris BioPharma Inc, Enzo Biochem Inc, F. Hoffmann-La Roche Ltd, Gador SA, GL Pharm Tech Corp, Glide Pharmaceutical Technologies Ltd, Hanmi Pharmaceuticals Co Ltd, Haoma Medica Ltd, Immunovo BV, Immunwork Inc, Intas Pharmaceuticals Ltd, Ipsen SA, Kaken Pharmaceutical Co Ltd, Lead Discovery Center GmbH, Ligand Pharmaceuticals Inc, Lotus Pharmaceutical Co Ltd, Lupin Ltd, Merck & Co Inc, Mereo Biopharma Group Plc, NIBEC, Omeros Corp, Oncobiologics Inc, Osteologix Holdings Plc, Paras Biopharmaceuticals Finland Oy, Pfenex Inc, PhytoHealth Corp, R Pharm, Ribomic Inc, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, Shin Poong PharmCo Ltd, Sinil Pharmaceutical Co Ltd, Stelis Biopharma Pvt Ltd, Sumitomo Dainippon Pharma Co Ltd, Terpenoid Therapeutics Inc, TSH Biopharm Corporation Ltd, Uni-Bio Science Group Ltd, Viking Therapeutics Inc, Wroclawskie Centrum Badan EIT+ Sp z oo, Yooyoung Pharm Co Ltd, Zydus Cadila Healthcare Ltd

Osteoporosis Therapeutic Products under Development, Key Players in Osteoporosis Therapeutics, Osteoporosis Pipeline Overview, Osteoporosis Pipeline, Osteoporosis Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand